NCT02888418Unknown1 期
Random, Double Blind, Placebo Controlled Phase I Clinical Trials to Estimate the Safety and Preliminary Immunogenicity of Tetravalent Recombinant Human Papilloma Virus Vaccine (6,11,16,18 Type)(Hansenula Polymorpha) in Women of 9 to 30 Years Old and Men of 9 to 17 Years Old
Beijing Chaoyang District Centre for Disease Control and Prevention0 个研究点目标入组 135 人开始时间: 2016年10月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 135
- 主要终点
- Evaluate the Rate of Adverse reactions of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17
研究概览
简要总结
This study evaluates the safety of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women of 9 to 30 years old and men of 9 to 17 years old and preliminarily explore the immunogenicity.
135 people are enrolled in total, including 45 women of 18 to 30 years old and 90 people of 9 to 17 years old. Among the first group, 30 women will be inoculated studied vaccine and 15 women will be inoculated placebo. Among the second group, there are 45 women and 45 men, 30 women and 30 men in vaccine group and 15 women and 15 men in placebo group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 9 Years 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Requirements of age: males of 9 to 17 years old, females of 9 to 30 years old.
- •Willing to provide the statutory certificate of identity.
- •For subjects of 18 to 30 years old, they should be able to understand the clinical trials and agreed to sign the informed consent; for subjects of 9 to 17 years old, their guardian should be able to understand the clinical trial, and sign informed consent together with subjects.
- •Female subjects have no pregnancy and birth plans in the 7 months after being enrolled, and agree to take effective contraception during this period.
排除标准
- •People with history of cervical cancer or HPV infection related diseases such as condyloma
- •People with a history of severe allergic reactions requiring medical intervention (such as garget, difficult breathing, hypotension or shock)
- •People with a history of serious side effects after vaccination or severe allergic reaction to food or drugs
- •People with epilepsy or a history of mental illness
- •People in immune deficiency or diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases, people with immunosuppressive therapy in the past six months.
- •People with serious liver or kidney disease, cardiovascular disease, severe hypertension, diabetes, cancer, all kinds of infectious disease and acute disease or in acute attack period of chronic diseases
- •Asplenia, functional asplenia, and any situation leading to asplenia or splenectomize.
- •People diagnosed by doctors with coagulation dysfunction (such as the lack of clotting factors, disorders of blood coagulation and blood platelet disorders), apparent bruises or blood coagulation disorders;
- •People given whole blood, plasma or immunoglobulin therapy within 3 months before vaccination.
- •People get any vaccine within 14 days before the trial.
- •People with fever before vaccination, axillary temperature higher than 37.0 ℃.
- •Females in suckling period, pregnancy (pregnancy test positive) or prepared to be pregnant.
- •People with abnormal laboratory index. (slight abnormity is except if judged with no clinical significance by doctors.)
- •People has gotten HPV vaccine before; people has used or plans to use other vaccine or unregistered products (drugs or vaccines) within 30 days before the first dose; people plans to participate in other clinical trials within 6 months after this clinical trial.
- •According to judgement of researchers, the subjects have any other factors that are not appropriate for this clinical trials.
- •The exclusion criteria for the second and third dose：
- •Urine pregnancy test are positive before vaccination.
- •Receiving blood products or other studied drugs after enrollment.
- •Suffering from serious illness or with serious adverse events that require continuous treatment.
- •Situations need to be excepted according to the judgement of researchers or the confirmation of Ethics Committee.
- •Newly occurred or discovered people that does not meet exclusion criteria of first dose after the first vaccination.
- •Delayed immunization:
- •Acute infectious disease, temperature being over 37.0 ℃or acute attack of chronic disease before inoculation.
- •Physical examination is abnormal on the day of vaccination.
- •Researchers think that the subjects belong to other temporary contraindications of vaccination.
- •Withdrawal criteria:
- •Any situation in exclusion criteria after enrollment.
- •People who suffers from diseases that need to be treated by immune inhibitors should be dropped out, in case of the harm of diseases that need to be treated by immune inhibitors.
- •Serious adverse events: events that need or prolong hospitalization, disability, threatening lives or death. Researchers decide whether to quit the trial.
- •Against the plan and deviation from the plan:
- •against the plan events
- •no appropriate informed consent for the subjects;
- •the subjects get into the research while do not meet the inclusion criteria or meet the exclusion criteria.
- •subjects use the vaccines that are not preserved as requested.
- •serious adverse event (SAE) does not be reported or timely reported.
- •subjects proactively use forbidden drugs (anti-allergic drug, antipyretic and analgesic, accepting systemic corticosteroids more than 2 mg/kg/day by intramuscular injection, oral or intravenous administration, continuing more than 14 days, or other immune inhibitors).
- •deviation from the plan
- •exceeding the Window of supervision.
- •the blood sample of subjects does not be collected or sample quantity is not enough to finish the test.
- •no enough interval with other vaccines.
结局指标
主要结局
Evaluate the Rate of Adverse reactions of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17
时间窗: 30 days
Adverse reactions associated with vaccine will be observed in subjects after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy.
次要结局
- Evaluate the seroconversion rate of HPV antibodies in serum after vaccination.(30 days)
研究者
相似试验
已完成
1 期
A Phase I Study of Quadrivalent HPV Recombinant VaccineHPV InfectionsNCT03085381Shanghai Bovax Biotechnology Co., Ltd.90
进行中（未招募）
3 期
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)Papillomavirus InfectionsNCT05285826Merck Sharp & Dohme LLC8,100
Unknown
1 期
Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy FemalesHuman PapillomavirusNCT01548118Shanghai Zerun Biotechnology Co.,Ltd160
进行中（未招募）
3 期
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)Papillomavirus InfectionsNCT03998254Merck Sharp & Dohme LLC6,000
已完成
3 期
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)HPV InfectionsNCT00834106Merck Sharp & Dohme LLC3,006